Common Stock SEC Reporting - Delinquent
OTC Pink No Information
Contact Info
  • 110 Founders Mill Ct
  • Roswell, GA 30075

Business Description

Not Available

Update Company Profile
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2012 10-Q
CIK 0000926287
Fiscal Year End 12/31
OTC Marketplace OTC Pink No Information
Profile Data
SIC - Industry Classification 2835 - Diagnostic substances
Incorporated In: NV, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Frank Marra President
Thomas A. Drees Founder, CEO
Company Directors
Frank Marra
Company Notes
  • Note=9-02 company is in the development stage focused on the research and development of PHER-O2, a synthetic red blood cell product
Service Providers
Accounting/Auditing Firm
HJ & Associates, LLC
50 W Broadway
Suite 600
Salt Lake City, UT, 84101
United States

Legal Counsel
Not Available
Investor Relations Firm
Not Available
SGUI Security Details
Share Structure
Market Value1 $289,873 a/o Nov 17, 2017
Authorized Shares 210,000,000 a/o May 26, 2017
Outstanding Shares 7,246,822 a/o Nov 13, 2012
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value 0.001
Shareholders of Record 567 a/o Apr 13, 2012
Short Selling Data
Short Interest 0 (-100%)
Mar 13, 2015
Significant Failures to Deliver No

1Market Value calculated only for respective security